New drug improves survival in patients with advanced triple-negative breast cancer
In short: A phase 3 clinical trial involving 468 patients found that sacituzumab govitecan significantly extended survival for those with metastatic triple-negative breast cancer who had already undergone taxane treatment. Compared to standard single-agent chemotherapy, patients receiving this antibody-drug conjugate saw longer progression-free and overall survival periods.
The study compared sacituzumab govitecan against various physician-chosen chemotherapies in patients with relapsed or refractory disease. While the drug showed significant benefits in survival, it was associated with higher rates of grade 3 or higher adverse events, such as neutropenia and diarrhea.
This trial was limited to patients without brain metastases.
Why it matters: Sacituzumab govitecan offers improved survival outcomes for patients with advanced triple-negative breast cancer compared to standard chemotherapy.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Bardia et al. (2021). Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. The New England journal of medicine.
To cite this card, link to https://intellectplus.co.uk/app/health-research-new-drug-improves-survival-in-patients-with-advanced-triple.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Clinical trials · More in Health · Latest · A–Z · All topics
